. 2017 Nov 3;9:545–554. doi: 10.2147/CLEP.S143563

Table S2.

Risk of incident malignancies and metastases – comparison of the hydroxychloroquine/chloroquine exposed and unexposed periods

	Exposed time Time at risk (year) Incidence rate (per 100 PY)	Unexposed time Time at risk (year) Incidence rate (per 100 PY)	Crude sHR^*	p-value	Adjusted sHR^*	p-value
Non-skin cancers	38,128	33,340	0.93 (0.78–1.10)	0.38	0.99 (0.83–1.17)^a	0.87
Non-skin cancers	0.76	0.91
Hematological malignancies	38,527	34,157	0.79 (0.52–1.21)	0.28	0.69 (0.44–1.07)^b	0.09
Hematological malignancies	0.12	0.16
Skin cancers	38,054	33,620	1.14 (0.92–1.41)	0.24	1.18 (0.95–1.48)^b	0.14
Skin cancers	0.54	0.51
Metastases	38,611	34,259	0.56 (0.36–0.86)	0.008	0.60 (0.38–0.94)^c	0.02
Metastases	0.09	0.19

Notes:

Chronically exposed compared to shortly exposed.

Adjusted on age, sex, underlying condition, smoking status, past history of cancer, deprivation index, and number of NSAIDs, metformin, vitamin D, glucocorticoids, methotrexate, and azathioprine prescriptions.

Adjusted on age, sex, underlying condition, smoking status, past history of cancer, deprivation index, and number of NSAIDs, vitamin D, glucocorticoids, methotrexate, and azathioprine prescriptions.

Adjusted on age, sex, underlying condition, smoking status, past history of cancer, deprivation index, and number of metformin, vitamin D, and glucocorticoids prescriptions.

Abbreviations: NSAIDs, nonsteroidal antiinflammatory drugs; PY, person-years; sHR, sub-distribution hazard ratio.